Skip to content

Postoperative Vocal Cord Palsy Between Double-lumen Endobronchial Tube and Bronchial Blocker for Robot-assisted Esophagectomy

Incidence of Postoperative Vocal Cord Palsy Between Double-lumen Endobronchial Tube and Bronchial Blocker for Robot-assisted Esophagectomy: a Multicenter Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06897501
Enrollment
202
Registered
2025-03-27
Start date
2025-04-14
Completion date
2026-12-31
Last updated
2025-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

One Lung Ventillation (OLV)

Keywords

robot-assisted esophagectomy, double-lumen endobronchial tube, bronchial blocker, vocal cord palsy

Brief summary

The goal of this clinical trial is to investigate whether the use of bronchial blocker could reduce the incidence of postoperative vocal cord palsy than the use of double-lumen endobronchial tube in robot-assisted esophagectomy.

Detailed description

Esophagectomy is a challenging surgery that usually requires one lung ventilation, and double-lumen endobronchial tubes and bronchial blockers are commonly used for one lung ventilation. Successful resection of recurrent laryngeal nerve lymph nodes during esophagectomy is important to survival and prevention of cancer recurrence, but there is a risk of postoperative vocal cord palsy due to the recurrent laryngeal nerve injury during the resection. Compared to a double-lumen endobronchial tube, the use of a bronchial blocker is expected to reduce the incidence of recurrent laryngeal nerve injury; however, few clinical studies compare the two devices in terms of the incidence of postoperative vocal cord palsy in robot-assisted esophagectomy. Therefore, the researchers aimed to investigate whether the use of bronchial blocker could reduce the incidence of postoperative vocal cord palsy than the use of double-lumen endobronchial tube in robot-assisted esophagectomy.

Interventions

Lung isolation for robot-assisted esophagectomy will be performed using bronchial blocker in this group.

DEVICEdouble-lumen endobronchial tube

Lung isolation for robot-assisted esophagectomy will be performed using double-lumen endobronchial tube in this group.

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 19 or older * American Society of Anesthesiologists physical status I - III * Elective robot-assisted esophagectomy * Any clinical stage of esophageal cancer * Patients who need recurrent laryngeal nerve lymph nodes resection

Exclusion criteria

* Patients who diagnosed vocal cord palsy or damage before surgery * Patients who need specific airway device due to airway problem * History of thoracic surgery * Emergency surgery * Combined surgery with other department * Pregnant or nursing women

Design outcomes

Primary

MeasureTime frameDescription
Postoperative vocal cord palsyOn postoperative day 7 after robot-assisted esophagectomyOn postoperative day 7, ENT doctor will performed the laryngoscopy exam to check the presence of vocal cord palsy.

Secondary

MeasureTime frameDescription
Number of resected recurrent laryngeal nerve lymph nodesAt the end of surgeryNumber of successfully resected recurrent laryngeal nerve lymph nodes will be counted at the end of surgery
Quality of one lung ventilationduring one lung ventilationduring one lung ventilation, anesthesiologists will evaluate the degree (excellent, fair, poor) of lung collapse.
Surgical difficulty reported by surgeonAt the end of surgerySurgeon will report the surgical difficulty (easy, moderate, difficult).

Countries

South Korea

Contacts

Primary ContactHyun Joo Ahn, MD PhD
hyunjooahn@skku.edu+821099330784
Backup ContactHeejoon Jeong, MD
heejoonjeong@skku.edu+821087282414

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026